<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03987698</url>
  </required_header>
  <id_info>
    <org_study_id>E2017232</org_study_id>
    <nct_id>NCT03987698</nct_id>
  </id_info>
  <brief_title>Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma</brief_title>
  <official_title>Phase II Clinical Study of PD-1 Monoclonal Antibody Combination With Autologous Cytokine-induced Killer Cell Immunotherapy in the Second-line Treatment of Metastatic Clear Cell Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, multicenter,open-label, phase II study is to evaluate the effects of PD-1&#xD;
      inhibitor combination with autologous cytokine-induced killer cell immunotherapy in the&#xD;
      second-line treatment of patients with metastatic clear cell renal cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the experimental group, patients received Camrelizumab injection (SHR-1210) 200mg d1, CIK&#xD;
      cells 1x10^10 d14; Q3W, for 4 cycles; then Camrelizumab injection maintenance treatment for 2&#xD;
      years. In the control group, patients received Camrelizumab injection 200mg d1, Q3W, for 2&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 year</time_frame>
    <description>PFS will be calculated from initiation of treatment until first progression, and patients alive in stable state will be censored at the time of last contact.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm 1: CIK+PD-1i</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1210 &amp; CIK cells&#xD;
SHR-1210,200mg/d,intravenous infusion,d1; CIK cells, 1x10^10 (10 billion ), intravenous infusion,d14; Q3W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SHR-1210,200mg/d,intravenous infusion,d1; Q3W.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SHR-1210</intervention_name>
    <description>SHR-1210 injection</description>
    <arm_group_label>Arm 1: CIK+PD-1i</arm_group_label>
    <arm_group_label>Arm 2: Control</arm_group_label>
    <other_name>PD-1 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CIK cells</intervention_name>
    <description>CIK cells injection</description>
    <arm_group_label>Arm 1: CIK+PD-1i</arm_group_label>
    <other_name>Cytokine-induced killer cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects who must meet all the following criteria should be selected:&#xD;
&#xD;
          1. Agreeing to participate in this study and signing a written informed consent.&#xD;
&#xD;
          2. Male or female,from 18 to 75 years (including 18 and 75 years).&#xD;
&#xD;
          3. The life expectancy will be longer than 3 months and can be followed up.&#xD;
&#xD;
          4. Patients with metastatic clear cell renal cell carcinoma were confirmed by&#xD;
             histological /cytological and imaging examinations. According to RECIST 1.1 standard,&#xD;
             there will be at least one measurable lesion.&#xD;
&#xD;
          5. Patients with disease progression after treatment with interferon or TKI.&#xD;
&#xD;
          6. ECOG score will be 0 or 1 within 7 days before randomization.&#xD;
&#xD;
          7. Within 14 days before the start of treatment, the results of laboratory test of blood&#xD;
             routine, liver, kidney function and hormone levels must be met the following criteria:&#xD;
&#xD;
             White blood cells: more than 3.0 × 109/L; Platelets: more than 100 × 109/L;&#xD;
             Neutrophils: more than 1.5 × 109/L; Hemoglobin: more than 80g/L; Serum glutamate&#xD;
             pyruvate transaminase: less than 2.5 folds of the upper normal limit (ULN); Serum&#xD;
             glutamic-oxal (o) acetic transaminase: less than 2.5 × ULN; Serum bilirubin: less than&#xD;
             1.25 × ULN; Serum creatinine: less than 1.25 × ULN. Cortisol and thyroid function will&#xD;
             be in the normal range.&#xD;
&#xD;
          8. The toxicity and side effects of previous chemotherapy will must be alleviated to&#xD;
             grade 1 or below (except hair loss).&#xD;
&#xD;
          9. Female subjects must take effective contraceptive measures throughout the study&#xD;
             period; serum or urine pregnancy test results must be negative during screening and&#xD;
             the whole study period.&#xD;
&#xD;
         10. Male subjects should take effective contraceptive measures from the beginning of&#xD;
             treatment to within 6 months after the end of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following criteria could not participate in this study:&#xD;
&#xD;
          1. Other malignant tumors needed treatment within five years.&#xD;
&#xD;
          2. Allogeneic tissue/organ transplantation.&#xD;
&#xD;
          3. Participating in research drug therapy within 4 weeks before the first administration&#xD;
             of the trial.&#xD;
&#xD;
          4. Systemic glucocorticoid therapy or any other form of immunosuppressive therapy (except&#xD;
             glucocorticoid preconditioned with docetaxel) is being administered within 3 days&#xD;
             before the first administration of the experimental therapy.&#xD;
&#xD;
          5. Received anti-tumor monoclonal antibody (mAb), chemotherapy, targeted small molecule&#xD;
             therapy or major surgery within 4 weeks before the first use of the drug; received&#xD;
             chest radiotherapy greater than 30 Gy within 6 months before the first use of the&#xD;
             drug; and received chest radiotherapy with 30 Gy or less within 1 month before the&#xD;
             first use of the drug.&#xD;
&#xD;
          6. Previous treatment with PD-1/PD-L1 antibodies.&#xD;
&#xD;
          7. Over the past two years, patients with active autoimmune diseases requiring systemic&#xD;
             treatment, such as the use of corticosteroids, or immunosuppressants. Substitution&#xD;
             therapy (such as thyroxine, insulin, or physiological corticosteroid replacement&#xD;
             therapy for adrenal or pituitary dysfunction) is not a systemic treatment.&#xD;
&#xD;
          8. Patients with congenital or acquired immunodeficiency (e.g. HIV-infected persons),&#xD;
             active hepatitis B (HBV-DNA &gt; 10^3 copies/ml) or hepatitis C (hepatitis C antibody&#xD;
             positive), and HCV-RNA higher than the detection limit of the analytical method.&#xD;
&#xD;
          9. Subjects with active central nervous system (CNS) metastases and/or cancerous&#xD;
             meningitis.&#xD;
&#xD;
         10. Patients with active infections requiring systemic intravenous therapy.&#xD;
&#xD;
         11. Mental illness or other illnesses, such as uncontrollable heart disease or pulmonary&#xD;
             disease, diabetes, etc.&#xD;
&#xD;
         12. Subjects who are known to be allergic to any of the constituents of the drug being&#xD;
             studied.&#xD;
&#xD;
         13. Subjects with a recent history of drug abuse (including alcohol) within one year.&#xD;
&#xD;
         14. Compliance is poor and can not cooperate with clinical research.&#xD;
&#xD;
         15. Female subjects who are pregnant or breastfeeding, or who are expected to be pregnant&#xD;
             during the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiubao Ren, MD. PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiubao Ren, MD. PhD.</last_name>
    <phone>86-22-23340123</phone>
    <phone_ext>3173</phone_ext>
    <email>liangcoh@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liang Liu, MD. Ph.D</last_name>
    <phone>86-22-23340123</phone>
    <phone_ext>3172</phone_ext>
    <email>renxiubao@tjmuch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Liu, MD. Ph.D</last_name>
      <phone>86-22-23340123</phone>
      <phone_ext>3172</phone_ext>
      <email>liangcoh@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiubao Ren, MD. PhD.</last_name>
      <phone>86-22-23340123</phone>
      <phone_ext>3173</phone_ext>
      <email>renxiubao@tjmuch.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 12, 2019</study_first_submitted>
  <study_first_submitted_qc>June 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2019</study_first_posted>
  <last_update_submitted>July 5, 2020</last_update_submitted>
  <last_update_submitted_qc>July 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

